Pathologic Features of Anti-Mi-2 Dermatomyositis.
Jantima TanboonMichio InoueShinya HirakawaHisateru TachimoriShinichiro HayashiSatoru NoguchiShigeaki SuzukiHanako Koguchi-YoshiokaManabu FujimotoIchizo NishinoPublished in: Neurology (2020)
This study provides Class II evidence that the muscle biopsies of DM patients with anti-Mi-2 autoantibodies are more likely to demonstrate higher severity scores in muscle fiber and inflammatory domains.